


## Corporate Profile

Now ideas for wellness  
**meiji**





Under the group slogan,  
 "Now ideas for wellness,"  
 the Meiji Group will create a cycle  
 in which everyone, society, and the earth,  
 can all smile in the new field of health.  
 We will transcend our own limits  
 with originality and ingenuity  
 without being bound by any framework.  
 Our challenge for the next 100 years is  
 just beginning.

Now ideas for wellness  
**meiji**

### Top Message

**In order to protect people  
 from infectious diseases,  
 we will contribute to solving  
 social issues through our business.**

We aim to enhance our lineup from vaccine-based prevention to treatments with antibacterial drugs as a leading company in the field of infectious diseases. We not only contribute to advances in pharmacological treatments by developing brand-name drugs, but also by providing high quality generic drugs within and outside Japan, ensuring appropriate drug costs across a wide variety of disorders, and improving access to pharmaceutical products. Moreover, while developing our business, we will strive to "reinforce Contract Manufacturing Outsourcing (CMO) and Contract Development Manufacturing Organizations (CDMO)". Under our group slogan, "Now ideas for wellness," we are striving to focus on the field of health. Relentless efforts with humility shall be our overriding motivation as a party involved in this life-related industry.



**Daikichiro Kobayashi**  
 President and Representative Director  
 Meiji Seika Pharma Co., Ltd.

### Group Philosophy


Our mission is to widen the world of "Tastiness and Enjoyment" and meet all expectations regarding "Health and Reassurance." Our wish is to be closely in tune with our customers' feelings and to always be there to brighten their daily lives. Our responsibility as "Food and Health" professionals is to continue finding innovative ways to meet our customers' needs, today and tomorrow.

Leading the control of infectious diseases through prevention and treatment. Producing new synergy by integrating our managerial resources.

# Our Vision

## Our Promise and Commitment for the 2026 Vision

We created the Meiji Group 2026 Vision as a strategy to maximize the strengths of the Meiji Group to grow further. We will follow through with this business plan and achieve the Vision successfully. Accordingly, we will improve our medium- and long-term corporate value.



## 2023 Medium-Term Business Plan

### Concept

### Promote the Meiji ROESG®\* Management effectively

Realize both profit growth and sustainability activities

Offering Health Value, our founding commitment, we reaffirm this pledge and will be a sustainable corporate group that shares our health values with people and societies around the world in order to achieve growth.

\*ROESG is a registered trademark for a managerial index developed by Prof. Kunio Ito of Hitotsubashi University.



Set up our own indicators by adding sustainability goals unique to the Meiji Group to the ROE and the ESG indicators by external evaluation organizations

### Key Issues

- Business strategy
- Improve business management using ROIC effectively
- Investing to grow business while constructing strong financial base
- Promote the Meiji Group Sustainability 2026 Vision

### Pharmaceutical segment

- Integrate business operations of Meiji Seika Pharma and KM Biologics (Strengthen vaccine business)
- Expand CMO\*1 and CDMO\*2 business


\*1: Contract Manufacturing Organization  
\*2: Contract Development and Manufacturing Organization

### Group-wide

Venture into new domains

## Integrate business operation of Meiji Seika Pharma and KM Biologics

We will integrate our managerial resources with those of KM Biologics, which became a group company in 2018, as the pharmaceutical segment of the Meiji Group, so as to create new synergies and further contribute to the prevention and treatment of infectious diseases. In order to prevent the spread of COVID-19 – perhaps our most pressing social issue – we will develop inactivated vaccines and promote therapeutic agents, etc. by utilizing Meiji Seika Pharma's unique manufacturing and development technologies as a leading manufacturer of antibacterial drugs with extensive knowhow regarding KM Biologics vaccine and production capabilities so as to cope with the COVID-19 pandemic.



# Our Sustainability

## Meiji Group Sustainability 2026 Vision

The Meiji Group Sustainability 2026 Vision is broken down into three themes: Healthier Lives, Caring for the Earth and Thriving, plus the shared theme: Sustainable Sourcing. We identify and set materiality issues and KPIs\* and promote specific sustainability activities and address social issues.

\*KPI: Key Performance Indicator



For further details ▶





Specializing in the fields of infectious diseases and central nervous system (CNS) disorders, and providing generic drugs to always support the public's health and lives.



## Ethical Pharmaceuticals Business

### Antibacterial drugs

After producing our first batch of penicillin in 1946, we quickly established ourselves as a leading manufacturer of antibacterial drugs. With a wide-ranging product lineup, we have secured our position as a leader in systemic antibacterial drugs. As for injectable penicillin-based antibacterial drugs, we are building a system to complete the value chain from production to sales entirely within the company, to ensure a stable supply.



### Central nervous system (CNS) disorders

We have an extensive lineup of therapeutics, such as Japan's first and only noradrenergic and specific serotonergic antidepressant (NaSSA), REFLEX; an antipsychotic drug, SYCREST. As for depression and Schizophrenia, there are an increasing number of patients against the backdrop of ageing, changes in lifestyle, and increased stress, etc. We strive to provide appropriate information via specialized MRS.



### Vaccines


We sell vaccines, such as influenza vaccines developed and produced by KM Biologics, DTaP-IPV vaccines containing antigens including the pertussis bacteria, and Japanese encephalitis vaccines. While the importance and need for vaccines have risen worldwide, we are contributing to improving public health with the steady supply of vaccines and information deemed important to prevent infectious diseases.



### Generic drugs

While being a manufacturer of brand-name drugs, we have long led the field in the generic drugs business. We offer high-quality generic drugs with great convenience, primarily in the fields of infectious disease and CNS disorders. Moreover, generic drugs are being manufactured by Medreich Ltd. in India, which joined our group in 2015. The Japanese strict quality management are achieved at low cost thanks to strict quality management.






### Overseas Business

## Accelerating business development worldwide, including the ASEAN market, where further growth is expected.

We started to export antibacterial drugs in the 1950s, and established a production system and sales network based on local subsidiaries, such as in Indonesia, Thailand, China and Spain. In 2015, Medreich Ltd. (India), which boasts extensive CMO/CDMO success and mass production facilities, joined our group, so we can now meet the expanding international demand for contract manufacturing of pharmaceutical products.



Thai Meiji Pharmaceuticals Co., Ltd.

Meiji Pharma USA Inc.



Meiji Pharma Spain, S.A.



Medreich Ltd



PT. Meiji Indonesian Pharmaceutical Industries

### Research and Development

We strive to grow the company centered on brand-name drugs and vaccines by applying new knowledge and technologies, while conducting research into generic drugs. In addition, we promote integrated R&D by applying the extensive experience in vaccine development accumulated by KM Biologics.

#### Pharmaceutical R&D Division

We are formulating development strategies for new seeds and products introduced from external organizations, conduct clinical studies in the most suitable countries and regions, and solicit approval for their manufacture and sales. We also promote the collection and formulation of medical evidence for the proper use of pharmaceutical drugs.



#### Pharmaceutical Research Center

In order to quickly and steadily supply useful and high quality pharmaceutical products that contribute to global medical care, we discover candidates for pharmaceutical products, analyze their structures, and evaluate their physical properties, as well as efficiently establishing specification testing methods and manufacturing processes for bulk drugs and formulations, industrialization, and cost cutting.



### Production

From the procurement of bulk drugs and raw materials to manufacturing, packaging and shipping, production is carried out under a strict GMP-based quality control system. The overall supply chain is centrally managed, and a system that ensures stable supply has been prepared. Reliable quality products are delivered to medical settings while all employees retain exceptional awareness of the need for quality.

### Reliability & Quality Assurance


Earning the trust of patients and healthcare professionals, while contributing to society, is adopted as our basic policy to guarantee reliability. In order to do that, we ensure and improve reliability by establishing and operating a quality management system. Reassuring products are delivered by collecting information on manufacturing and quality control, including raw material procurement, and promoting reliability assurance activities to provide information for proper use.



## History

We have long contributed to progress in pharmacological treatments for a wide range of diseases, providing drugs at an appropriate cost, and improving access to medicine.

- 1916 ○ Tokyo Confectionery Co., Ltd. (Tokyo Confectionery), the predecessor of Meiji Seika, is established.
- 1924 ○ Tokyo Confectionery changes its name to Meiji Seika Kaisha, Ltd. (Meiji Seika).
- 1946 ○ The pharmaceutical business is started beginning with production of penicillin.
- 1950 ● The antibiotic *STREPTOMYCIN MEIJI* is launched. Export of antibiotics begins.
- 1958 ● The first antibiotic originally made in Japan, *KANAMYCIN MEIJI*, is launched.
- 1989 ● The antianxiety drug *MEILAX* is launched.
- 1990 ● *HABEKACIN*, an antibacterial drug that is Japan's first treatment for methicillin-resistant *Staphylococcus aureus* (MRSA) infections, is launched.
- 1994 ● The antibiotic *MEIACT* is launched.
- 1998 ● Fully entered the generic drugs business.
- 1999 ● The antidepressant drug *DEPROMEL* is launched.
- 2009 ○ Meiji Seika and Meiji Dairies establish Meiji Holdings Co., Ltd. (Meiji Holdings), a joint holding company, and integrate their management. The antibiotic *ORAPENEM* and the antidepressant *REFLEX* are launched.
- 2011 ○ Meiji Seika Pharma Co., Ltd., a pharmaceutical company, begins operation. The herbicide *ZAXA* is launched.
- 2015 ○ Medreich Ltd. (India) joins the group. The antibiotic generic drug *TAZOPIPE MEIJI* is launched.
- 2016 ○ The antipsychotic drug *SYCREST* is launched. The anti-allergy drug *BILANOVA* is launched. Establishment of generic drugs manufacturing and sales subsidiary, Me Pharma.
- 2018 ○ KM Biologics Co., Ltd., which conducts research, development, and manufacturing of biologics including vaccines, joins the group. Influenza HA Vaccine "KMB" is launched.
- 2021 ● An anticancer drug *HIYASTA TABLETS* is launched.
- 2022 ○ Meiji Seika Pharmatech Co., Ltd. as an ethical pharmaceutical manufacturer is established.



PENICILLIN




KANAMYCIN



ORYZEMATE



REFLEX



SYCREST



BILANOVA



HIYASTA TABLETS

## Corporate Profile

### Meiji Seika Pharma Co., Ltd.

Established : October 9, 1916  
 President and Representative Director : Daikichiro Kobayashi  
 Number of Employees : 5,501 (As of March 31, 2023)  
 Main Businesses : Manufacturing and sale of ethical pharmaceuticals

Capital : ¥28.363 billion  
 Head Office : 4-16 Kyobashi 2-chome, Chuo-ku,  
 Tokyo 104-8002, Japan

## Operating Bases and Group Companies

### Japan

- **Head Office**
- **Branches**  
Hokkaido / Tohoku / Tokyo / Kanto / Chubu / Kansai / Chugoku & Shikoku / Kyushu
- **Research Laboratories**  
Pharmaceutical Research Center
- **Plants**  
Gifu
- **Group Companies**  
Meiji Seika Pharmatech Co., Ltd. / Me Pharma Co., Ltd. / OHKURA Pharmaceutical Co., Ltd. / Romeck Pharma, LLC / MIYAKO YUSO TRANSPORTATION CO., LTD.

### Overseas

- **Group Companies**  
Guangdong Meiji Pharmaceutical Co., Ltd. / PT. Meiji Indonesian Pharmaceutical Industries / Thai Meiji Pharmaceutical Co., Ltd. / Medreich Limited / Genovo Development Services Limited / Adcock Ingram Limited / Adcock Ingram Pharma Private Limited / Medreich Life care Limited / Medreich plc / Medreich Australia Pty Ltd. / Medreich Far East Limited / Inopharm Limited / Medreich New Zealand Limited / Meiji Pharma Spain, S.A. / Meiji Seika Europe B.V. / Meiji Pharma USA Inc.